

ANALYSIS OF NON-BLEEDING UTERINE FIBROIDS SYMPTOM (NBUFSQ) QUESTIONNAIRE  
DURING TREATMENT AND POST-TREATMENT FOLLOW-UP PERIODS  
(MODIFIED INTENT-TO-TREAT ANALYSIS SET - COHORT 1)

				WITHIN GROUP			MODEL-BASED BETWEEN GROUP COMPARISON					
				----- CHANGE FROM BASELINE -----			----- COMPARE TO PLACEBO -----					
VARIABLE							DIFFERENCE					
TIME POINT		BASE	VISIT				LS	OF LS				
TREATMENT	N	MEAN	MEAN	MEAN	SD	95% CI	MEANS (SE)	MEANS (SE)	95% CI		P-VALUE	\$
SUM OF SCORES OF Q1 TO Q6												
BASELINE												
PLACEBO	32		16.2				16.2 (2.22)					
ELAGOLIX 300 MG BID	32		16.7				16.7 (2.22)	0.5 (3.14)	(-5.74, 6.69)		0.880	
ELAGOLIX 300 MG BID												
+E2/NETA (LD)	32		11.3				11.3 (2.22)	-4.9 (3.14)	(-11.15, 1.29)		0.119	
ELAGOLIX 300 MG BID												
+E2/NETA (SD)	29		17.5				17.5 (2.33)	1.3 (3.22)	(-5.11, 7.64)		0.695	

FINAL MONTH #

PLACEBO	37	16.2	10.9	-5.3	13.19	(-10.04, -0.53)	-5.0 (1.81)				
ELAGOLIX 300 MG BID	34	16.7	8.7	-6.7	11.94	(-11.11, -2.35)	-6.5 (1.84)	-1.5 (2.58)	(-6.65, 3.59)	0.556	
ELAGOLIX 300 MG BID											
+E2/NETA(LD)	33	11.6	7.1	-4.1	10.15	(-7.92, -0.34)	-6.1 (1.90)	-1.1 (2.63)	(-6.33, 4.09)	0.672	
ELAGOLIX 300 MG BID											
+E2/NETA(SD)	31	18.0	16.6	-3.5	12.59	(-8.58, 1.59)	-2.0 (2.02)	3.0 (2.71)	(-2.39, 8.36)	0.274	